VK2735 for Weight Management Phase 3

Prior treatment

• Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
• Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

Other illness

• History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
• Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)
• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
• History of acute or chronic pancreatitis

Lab values

• Treatment with glucose-lowering agent(s) within 90 days before screening

Other

• Self-reported body weight change of 5% or more within 3 months of screening

• Age ≥18 years of age at the time of signing the informed consent
• Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)
  • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
  • Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure
  • BMI calculated at the Screening visit will be used to determine eligibility